Reviewing Journey Medical (DERM) & Its Peers

Journey Medical (NASDAQ:DERM) is one of 996 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Journey Medical to related businesses based on the strength of its dividends, profitability, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Journey Medical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Journey Medical	-4.87%	-46.48%	-4.99%
Journey Medical Competitors	-2,554.11%	-203.85%	-29.63%

Risk and Volatility

Journey Medical has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Journey Medical’s peers have a beta of 0.85, indicating that their average stock price is 15% less volatile than the S&P 500.

Valuation and Earnings

This table compares Journey Medical and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Journey Medical	$79.18 million	-$3.85 million	-10.51
Journey Medical Competitors	$2.14 billion	$149.57 million	-4.89

Journey Medical’s peers have higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 19.4% of Journey Medical shares are held by company insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Journey Medical and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	0	0	1	0	3.00
Journey Medical Competitors	6172	18319	44043	909	2.57

Journey Medical currently has a consensus target price of $8.50, indicating a potential upside of 130.98%. As a group, “Pharmaceutical preparations” companies have a potential upside of 68.84%. Given Journey Medical’s stronger consensus rating and higher possible upside, equities analysts plainly believe Journey Medical is more favorable than its peers.

Summary

Journey Medical beats its peers on 7 of the 12 factors compared.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.